Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2008-03-04
2008-03-04
Yu, Misook (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Reexamination Certificate
active
07339027
ABSTRACT:
A novel fusion protein, comprising a receptor-antagonizing domain and an angiogensis inhibiting domain, characterized, for example, by its ability to block apoptosis and/or inhibit endocrine response, is useful in treating cancer. For example, a human prolactin antagonist-endostatin fusion protein combines apoptosis induction and angiogenesis inhibition to combat cancer.
REFERENCES:
patent: 5854205 (1998-12-01), O'Reilly et al.
patent: 6114305 (2000-09-01), Guemene et al.
patent: 6342221 (2002-01-01), Thorpe et al.
patent: 6803211 (2004-10-01), Tong et al.
patent: 2002/0068043 (2002-06-01), Chen et al.
patent: WO 99/16889 (1999-04-01), None
patent: WO 99/46371 (1999-09-01), None
patent: WO 01/70985 (2001-09-01), None
Gura, Science, 1997, 278:1041-1042.
Jain, Sci. Am., 1994, 271:58-65).
Curti, Crit. Rev. in Oncology/Hematology, 1993, 14:29-39.
Verheul et al, J Pathol 202:5-13, 2004.
Pidgeon et al, Br. J Cancer 85:273-278, Jul. 20, 2001.
Sakkoula et al Br. J Pharm. 122:793-795, 1997.
Clevenger et al., “Expression of Prolactin and Prolactin Receptor in Human Breast Carcinoma”, American Journal of Pathology, vol. 146 No. 3, pp. 695-705, Mar. 1995.
Ginsburg et al., “Prolactin Synthesis and Secretion by Human Breast Cancer Cells”, Cancer Research, vol. 55, No. 11; pp. 2591-2595, Jun. 1995.
Wennbo et al., “Transgenic Mice Overexpressing the Prolactin Gene Develop Dramatic Enlargement of the Prostate Gland”, Endocrinology, vol. 138, No. 10, pp. 4410-4415, Apr. 1997.
Aragona et al., “Specific Prolactin Binding Sites in the Prostate and Testis of Rats”, Endocrinology, vol. 97, No. 3, pp. 677-684, Jan. 1975.
Leake et al., “Characterization of the Prolactin Receptor in Human Prostate”, Journal of Endocrinology, vol. 99, pp. 321-328, Apr. 1983.
Hammond et al., “Serum FSH, LH and Prolactin and Nornal Males and Patients with Prostatic Diseases”, Clinical Endocrinology, vol. 7, No. 2, pp. 129-135, Aug. 1977.
“Influence of Age on Serum Prolactin Levels in Women and Men”, British Medical Journal, vol. 4, No. 5999, pp. 738-739, Dec. 1975.
Zhang et al., “A Novel Design of Targeted Endocrine and Cytokine Therapy for Breast Cancer”, Clinical Cancer Research, vol. 8, pp. 1196-1205, Apr. 2002.
Chen et al., “A Human Prolactin Antagonist, hPRL-G129R, Inhibits Breast Cancer Cell Proliferation through Induction of Apoptosis”, Clinical Cancer Research, vol. 5, pp. 3583-3593, Nov. 1999.
Altschul et al., “Basic Local Alignment Search Tool”, Journal of Molecular Biology, vol. 215, No. 3, pp. 403-410, Oct. 1990.
Gish et al., “Identification of Protein Coding Regions by Database Similarity Search”, Nature Genetics, vol. 3, No. 3, pp. 266-272, Mar. 1993.
Madden et al., “Applications of Network BLAST Server”, Methods in Enzymology, vol. 266, pp. 131-141, 1996.
Altschul et al., “Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Progams”, Nucleic Acids Research, vol. 25, No. 17, pp. 3389-3402, Sep. 1997.
Zhang et al., “PowerBLAST: A New Network BLAST Application for Interactive or Automated Sequence Analysis and Annotation”, Genome Research, vol. 7, pp. 649-656, 1997.
Osol, Arthur, Remington's 16thEdition, Pharmaceutical Sciences, 1980. (Table of Contents).
Zhang et al., “A Novel Design of Targeted Endocrine and Cytokine Therapy for Breast Cancer”, Clinical Cancer Research, vol. 8, pp. 1196-1205, Apr. 2002.
Database DISSABS on STN, AN 2003:.7678, Beck et al., “Relationship of the prolactin antagonist, G129R, with Bc1-2 and its therapeutic effects as a fusion protein with endostatin for the treatment of breast cancer”, Dissertation Abstracts International, 2002, vol. 63, No. 11B, p. 5056.
Eskes et al.Mol. Cell. Biol., 20(3):929-935 (2000).
Esposti, M.D.,Apoptosis, 7(5):433-440 (2002).
Hu et al.Apoptosis, 8(3):277-289 (2003).
Letai et al.Cancer Cell, 2(3):183-192 (2002).
Liu et al.Biochem. Biophys. Res. Commun., 330(3):865-870 (2005).
Lutter et al.Nat. Cell Biol., 2(10):754-756 (2000).
Scorrano et al.Dev. Cell, 2(1):55-67 (2002).
Wang et al.Genes Dev., 10(22):2859-2869 (1996).
Zhai et al.Eur. J. Biochem., 268(1):48-55 (2001).
Partial European Search Report for EP 02 79 9347, mailed Jul. 26, 2006.
Malonne et al., “Mechanisms of Tumor Angiogenesis and Therapeutic Implications: Angiogenesis Inhibitors,” vol. 17, No. 1, 1999, pp. 1-14.
Chen et al., “In vivo Studies of the Anti-Tumor Effects of a Human Prolactin Antagonist, HPRL-G129R,” vol. 20, Apr. 2002, pp. 813-818.
Beck et al., “Prolactin Antagonist-Endostatin Fusion Protein as a Targeted Dual-Functional Therapeutic Agent for Breast Cancer,” vol. 63, No. 13, Jul. 2003, pp. 3598-3604.
Llovera et al., “Human Protein (HPRL) Antagonists Inhibit HPRL-Activated Signaling Pathways Involved in Breast cancer Cell Proliferation,” vol. 19, No. 41, Sep. 2000, pp. 4695-4705.
Foley & Lardner LLP
GHC Research Development Corporation
Halvorson Mark
Yu Misook
LandOfFree
Human prolactin antagonist-angiogenesis inhibitor fusion... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human prolactin antagonist-angiogenesis inhibitor fusion..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human prolactin antagonist-angiogenesis inhibitor fusion... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2786743